Sponsor
Neal Patrick Dunn
Representative · R-FL
Representative · R-FL
The bill aims to improve patient safety and transparency by creating an LDT-specific regulatory regime and public database while imposing substantial new compliance obligations and legal complexity that could raise costs for labs, disadvantage smaller providers, and risk service disruptions during the transition.
Patients (especially those with chronic conditions) and hospital/clinical laboratories will face clearer, LDT-specific federal oversight with explicit standards, quality-system requirements, and adverse-event/test-error reporting, improving test reliability and speeding detection of harmful tests.
Clinicians, patients, payers, and labs gain a centralized public database and more transparent, participatory rulemaking (public input, annual open-door forums, RFIs, 5-year reviews), making information about available LDTs, their regulatory status, and evolving standards easier to find and understand.
Clinical laboratories and test developers get a predictable transition path (clear regulatory deadlines, a 2-year implementation window, and temporary preservation of existing FDA authorizations for some tests), reducing immediate disruption and giving industry time to adapt.
Hospitals, independent and smaller clinical laboratories, and ultimately patients face substantial new compliance costs and administrative burdens (registration, premarket submissions, quality systems, reporting, potential fees) that may strain smaller providers and could raise test prices.
Patients (especially those needing specialized/rare-tests) and providers risk disrupted care because the Secretary can suspend LDTs and some tests will face transitional regulatory changes that may pause availability or expose patients to differing standards during remediation or reclassification.
Manufacturers, labs, and providers will face legal complexity and regulatory uncertainty from reclassifying LDTs outside existing FD&C Act device rules, immediate definitional changes, and a potentially confusing two-track compliance environment during the transition.
Based on analysis of 4 sections of legislative text.
Creates a new HHS/FDA regulatory regime for laboratory-developed tests requiring registration, many premarket submissions, quality and reporting controls, and CLIA transparency reforms.
Official title: To amend the Public Health Services Act, commonly referred to as the "Clinical Laboratory Improvement Amendments" or "CLIA", with respect to laboratory developed tests, and for other purposes.
Introduced May 19, 2026 by Neal Patrick Dunn · Last progress May 19, 2026
Creates a new HHS/FDA regulatory framework for laboratory-developed tests (LDTs), requiring registration, premarket submissions for many tests, quality system controls, adverse event reporting, and specific exemptions. It also directs immediate and phased rulemaking, temporarily clarifies the device status of some tests, and requires increased transparency, stakeholder engagement, and periodic review of CLIA rules by HHS and CMS.